CDT Equity (NASDAQ:CDT) Raised to “Sell” at Wall Street Zen

CDT Equity (NASDAQ:CDT) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CDT Equity in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, CDT Equity currently has a consensus rating of “Sell”.

CDT Equity Stock Performance

Shares of CDT opened at $2.93 on Friday. The company has a market capitalization of $1.44 million, a PE ratio of -0.00 and a beta of 1.52. The company’s 50 day moving average price is $6.33 and its 200 day moving average price is $96.07. CDT Equity has a 52 week low of $2.53 and a 52 week high of $3,800.00.

CDT Equity (NASDAQ:CDT) last released its earnings results on Wednesday, July 15th. The company reported ($55.60) earnings per share (EPS) for the quarter.

About CDT Equity

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.